Merck Issues Statement on FDA Advisory Committee Meeting Results for Suvorexant

Merck

, known as MSD outside the United States and Canada, today provided the following statement after the conclusion of the Peripheral and Central Nervous System Drugs Advisory Committee meeting of the U.S. Food and Drug Administration (FDA) about suvorexant, Merck's investigational medicine to treat insomnia. “We are excited about the potential of suvorexant as a new and different approach to treating insomnia, a serious condition that affects up to one-third of the adult population,” said Darryle Schoepp, Ph.D., senior vice president and head of Neuroscience and Ophthalmology, Merck Research Laboratories. “Today's votes and discussion bring us one step closer to providing physicians with another option to help patients struggling with insomnia. We